Payment overview · 2025
General Payments
$1,502.29
78 reported records · 16 companies
Healthcare provider profile · identity verified
Daniel Isaac Piotter, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHREVEPORT, LA · NPI 1225490600
Verified facts
What the public records show
CMS Open Payments records show Daniel Isaac Piotter, MD received $1,502.29 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Farxiga, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aristada by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $228.84 | 15.2% | 15 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $203.67 | 13.6% | 13 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $161.50 | 10.8% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $155.22 | 10.3% | 9 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $127.69 | 8.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.36 | 7.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $108.84 | 7.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.04 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.06 | 4.9% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.28 | 4.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.33 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.44 | 2.6% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $35.98 | 2.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $32.61 | 2.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.03 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.40 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,502.29 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $224.75 | 14 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $203.67 | 13 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $161.50 | 12 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $161.50 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $155.22 | 9 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $127.69 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $109.36 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.84 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $97.07 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $64.28 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.38 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.14 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $4.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $4.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 222 | 48 |
| Gabapentin | Gabapentin | 217 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 35 |
| Lisinopril | Lisinopril | 139 | 34 |
| Ozempic | Semaglutide | 102 | 21 |
| Farxiga | Dapagliflozin Propanediol | 100 | 22 |
| Mounjaro | Tirzepatide | 100 | 17 |
| Trazodone Hcl | Trazodone Hcl | 96 | 27 |
| Omeprazole | Omeprazole | 85 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 24 |
| Eliquis | Apixaban | 81 | 16 |
| Carvedilol | Carvedilol | 75 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 14 |
| Furosemide | Furosemide | 70 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 16 |
| Potassium Chloride | Potassium Chloride | 69 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 68 | 20 |
| Losartan Potassium | Losartan Potassium | 66 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 18 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Prednisone | Prednisone | 50 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Jardiance | Empagliflozin | 46 | 14 |
| Meloxicam | Meloxicam | 45 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 15 |
| Tramadol Hcl | Tramadol Hcl | 45 | 19 |
| Metformin Hcl | Metformin Hcl | 44 | 14 |
| Famotidine | Famotidine | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 14 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Sulfasalazine | Sulfasalazine | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Ondansetron Odt | Ondansetron | 35 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | 15 |
| Naproxen | Naproxen | 32 | 29 |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Linzess | Linaclotide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,502.29 · 78 records | ABBVIE INC. | ARISTADA, Auvelity, Azstarys, BREZTRI, CAPLYTA, COBENFY, FANAPT, FARXIGA, IBSRELA, Kerendia, LYBALVI, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, bio-ConneKt | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error